FDA staff cuts are already impacting regulatory work,...

2025-04-10 11:37:31 ET More on Arcutis Biotherapeutics, Beam Therapeutics, etc. Pfizer: Anticipating A Game-Changer Soon Pfizer: Best-In-Class Dividend Yield Together With Dirt Cheap Valuation Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) Nearly 50% of the S&P 500 is in oversold territory or on the brink of it J&J upgraded; Pfizer, AbbVie downgraded as Goldman reviews U.S. biopharma coverage Read the full article on Seeking Alpha For further details see: FDA staff cuts are already impacting regulatory work, Biotech leaders warn